- Home
- PLL vs LYEL Comparison
PLL vs LYEL Comparison
Compare PLL & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLL
- LYEL
- Stock Information
- Founded
- PLL 2016
- LYEL 2018
- Country
- PLL United States
- LYEL United States
- Employees
- PLL N/A
- LYEL N/A
- Industry
- PLL Other Metals and Minerals
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- PLL Basic Materials
- LYEL Health Care
- Exchange
- PLL Nasdaq
- LYEL Nasdaq
- Market Cap
- PLL 195.1M
- LYEL 203.9M
- IPO Year
- PLL 2017
- LYEL 2021
- Fundamental
- Price
- PLL $9.08
- LYEL $0.58
- Analyst Decision
- PLL Buy
- LYEL Sell
- Analyst Count
- PLL 9
- LYEL 2
- Target Price
- PLL $22.04
- LYEL $1.00
- AVG Volume (30 Days)
- PLL 391.4K
- LYEL 1.1M
- Earning Date
- PLL 02-20-2025
- LYEL 02-26-2025
- Dividend Yield
- PLL N/A
- LYEL N/A
- EPS Growth
- PLL N/A
- LYEL N/A
- EPS
- PLL N/A
- LYEL N/A
- Revenue
- PLL $46,981,000.00
- LYEL $63,000.00
- Revenue This Year
- PLL $126.75
- LYEL N/A
- Revenue Next Year
- PLL $35.26
- LYEL N/A
- P/E Ratio
- PLL N/A
- LYEL N/A
- Revenue Growth
- PLL N/A
- LYEL N/A
- 52 Week Low
- PLL $6.57
- LYEL $0.55
- 52 Week High
- PLL $18.72
- LYEL $3.26
- Technical
- Relative Strength Index (RSI)
- PLL 41.80
- LYEL 34.70
- Support Level
- PLL $8.59
- LYEL $0.55
- Resistance Level
- PLL $9.53
- LYEL $0.62
- Average True Range (ATR)
- PLL 0.54
- LYEL 0.04
- MACD
- PLL 0.10
- LYEL 0.01
- Stochastic Oscillator
- PLL 30.23
- LYEL 14.24
About PLL Piedmont Lithium Inc.
Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.